Anti-Inflammatory Effects of Rosiglitazone in Patients With Stage 4 and 5 Chronic Kidney Disease

• Status: Withdrawn
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study in patients with stage 4 and 5 chronic kidney disease is to determine whether rosiglitazone can reduce inflammatory markers and to investigate its effect on intima media thickness, calcification and pulse wave velocity.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Leiden University Medical Center
• Treatments: Anti-Inflammatory Agents; Rosiglitazone

Criteria

Inclusion Criteria:

• Written consent

• Over 18 years of age

• Stage 4 or 5 chronic kidney disease according the K/DOQI guidelines

Exclusion Criteria:

• Life span of less than one year

• Alcohol abuse

• Transaminases > 2.5 times the upper limit

• Diabetes mellitus

• Pregnancy

• Cardiac disease with marked limitation of functional capacity (NYHA III or IV)

• Use of immunosuppressant agents